Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | LOX | P28300 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.42 |
| ▸ | HRH2 | P25021 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6469273 | 0.82 | HRH3 (0.52) | HRH3KCNH2LTA4HLOXGAA | |
| SCHEMBL2921597 | 0.74 | ESR1 (0.58) | HRH3KCNH2LOXGAAMEN1 | |
| SCHEMBL56319 | 0.74 | LOX (0.57) | HRH3KCNH2LOXGAATSHR | |
| SCHEMBL13604236 | 0.74 | KMT2A (0.71) | LTA4HLOXMEN1KMT2A | |
| SCHEMBL3747083 | 0.72 | AOC3 (0.56) | HRH3KCNH2 | |
| SCHEMBL3747085 | 0.72 | AOC3 (0.56) | HRH3KCNH2 | |
| SCHEMBL3747078 | 0.72 | AOC3 (0.56) | HRH3KCNH2 | |
| SCHEMBL2922255 | 0.72 | ESR1 (0.56) | LTA4HLOXGAAMEN1KMT2A | |
| SCHEMBL14476103 | 0.72 | MEN1 (0.73) | LTA4HLOXMEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2923094 | 0.72 | AOC3 (0.55) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060189650-A1 | Novel piperidine derivatives as modulators of chemokine receptor ccr5 | ASTRAZENECA AB (SE) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189650-A1 | Novel piperidine derivatives as modulators of chemokine receptor ccr5 | CCR5, CCR2, CCR1 | HRH3 148/4885KCNH2 2437/4885LTA4H 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.